Cargando…

A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized, Single‐Dose, Phase 1 Crossover Trial

Atogepant is a selective, oral calcitonin gene–related peptide receptor antagonist in development for preventive treatment of migraine. This randomized, double‐blind, phase 1 crossover study evaluated the cardiac repolarization effect of a single supratherapeutic (300 mg) atogepant dose vs placebo i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boinpally, Ramesh, McNamee, Brian, Yao, Li, Butler, Matthew, McGeeney, Danielle, Borbridge, Lisa, Periclou, Antonia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453716/ https://www.ncbi.nlm.nih.gov/pubmed/33942560 http://dx.doi.org/10.1002/cpdd.940

Ejemplares similares

Single Therapeutic and Supratherapeutic Doses of Ubrogepant Do Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized Trial
por: Jakate, Abhijeet, et al.
Publicado: (2019)

Single‐Dose Pharmacokinetics and Safety of Atogepant in Adults With Hepatic Impairment: Results From an Open‐Label, Phase 1 Trial
por: Boinpally, Ramesh, et al.
Publicado: (2021)

An Open‐Label Study to Evaluate the Effect of Eluxadoline on the Single‐Dose Pharmacokinetics of Midazolam in Healthy Participants
por: Boinpally, Ramesh, et al.
Publicado: (2022)

Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans
por: Jakate, Abhijeet, et al.
Publicado: (2020)

Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene‒related peptide‐targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug–drug interaction study
por: Jakate, Abhijeet, et al.
Publicado: (2021)

Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization
por: Langenickel, Thomas H., et al.
Publicado: (2016)

Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial
por: Boinpally, Ramesh, et al.
Publicado: (2021)

Supratherapeutic dose evaluation and effect of lesinurad on cardiac repolarization: a thorough QT/QTc study
por: Shen, Zancong, et al.
Publicado: (2016)

A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer
por: Lush, Richard M., et al.
Publicado: (2012)

A Thorough QT Study to Evaluate the Effects of a Supratherapeutic Dose of Sertraline on Cardiac Repolarization in Healthy Subjects
por: Abbas, Richat, et al.
Publicado: (2019)

An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers: A phase I, randomized study
por: Kallend, David, et al.
Publicado: (2022)

Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants
por: Ankrom, Wendy, et al.
Publicado: (2020)

A focus on pleasure? Desire and disgust in group work with young men
por: McGeeney, Ester
Publicado: (2015)

Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults
por: Min, K. Chris, et al.
Publicado: (2020)

A Novel Once-Daily Fixed-Dose Combination of Memantine Extended Release and Donepezil for the Treatment of Moderate to Severe Alzheimer’s Disease: Two Phase I Studies in Healthy Volunteers
por: Boinpally, Ramesh, et al.
Publicado: (2015)

Valsalva-induced cluster headache
por: McGeeney, B. E.
Publicado: (2006)

Single‐dose Pharmacokinetics of Eluxadoline in Healthy Participants With Normal Renal Function and Participants With Renal Impairment
por: Boinpally, Ramesh, et al.
Publicado: (2022)

A Randomized, Single‐Blind, Placebo‐Controlled, 3‐Way Crossover Study to Evaluate the Effect of Therapeutic and Supratherapeutic Doses of Edaravone on QT/QTc Interval in Healthy Subjects
por: Shimizu, Hidetoshi, et al.
Publicado: (2020)

No effect of a single supratherapeutic dose of lersivirine, a next-generation NNRTI, on QTc interval in healthy subjects
por: Vourvahis, M, et al.
Publicado: (2010)

Single‐Dose Pharmacokinetics and Safety of Ubrogepant in Adults With Hepatic Impairment: Results From an Open‐Label, Phase 1 Trial
por: Boinpally, Ramesh, et al.
Publicado: (2022)

Atogepant for the prevention of episodic migraine in adults
por: Switzer, Maranda Paige, et al.
Publicado: (2022)

Electrocardiographic Effects of a Supratherapeutic Dose of WCK 2349, a Benzoquinolizine Fluoroquinolone
por: Mason, Jay W., et al.
Publicado: (2018)

Lenalidomide at Therapeutic and Supratherapeutic Doses Does Not Prolong QTc Intervals in the Thorough QTc Study Conducted in Healthy Men
por: Chen, Nianhang, et al.
Publicado: (2013)

Thorough QT/QTc Evaluation of the Cardiac Safety of Secnidazole at Therapeutic and Supratherapeutic Doses in Healthy Individuals
por: Darpo, Borje, et al.
Publicado: (2017)

Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans
por: Chen, Laishun, et al.
Publicado: (2015)

A randomized, multicenter trial assessing the effects of rapastinel compared to ketamine, alprazolam, and placebo on simulated driving performance
por: Su, Shengfang, et al.
Publicado: (2021)

Supratherapeutic anti-factor Xa levels in patients receiving prophylactic doses of enoxaparin: A case series
por: Pannucci, Christopher J., et al.
Publicado: (2016)

Role of Atogepant in the Treatment of Episodic Migraines: Clinical Perspectives and Considerations
por: Cohen, Fred, et al.
Publicado: (2022)

Novel Oral CGRP Receptor Antagonist Atogepant in the Prevention of Migraine
por: Chowdhury, Selia, et al.
Publicado: (2023)

Effect of Therapeutic and Supratherapeutic Doses of Vonoprazan on the QT/QTc Interval in a Phase I Randomized Study in Healthy Subjects
por: Astruc, B, et al.
Publicado: (2017)

Spontaneous Epiglottic Hematoma Secondary to Supratherapeutic Anticoagulation
por: Koch, Cody A., et al.
Publicado: (2010)

A Retrospective Review of Supratherapeutic Modafinil Exposures
por: Carstairs, Shaun D., et al.
Publicado: (2010)

Similar pharmacokinetics of three dosing regimens comprising two oral delayed‐release mesalamine formulations in healthy adult volunteers: Randomised, open‐label, parallel‐group study
por: Vande Casteele, Niels, et al.
Publicado: (2020)

Has the short-term effect of black smoke exposure on pneumonia mortality been underestimated because hospitalisation is ignored: findings from a case-crossover study
por: Gittins, Matthew, et al.
Publicado: (2013)

The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials
por: Tao, Xinyu, et al.
Publicado: (2022)

The application of transcriptional benchmark dose modeling for deriving thresholds of effects associated with solar‐simulated ultraviolet radiation exposure
por: Qutob, Sami S., et al.
Publicado: (2018)

Risk Factors for Interpersonal Violence in Prison: Evidence From Longitudinal Administrative Prison Data in Northern Ireland
por: Butler, Michelle, et al.
Publicado: (2021)

Consensus for the management of pancreatic exocrine insufficiency: UK practical guidelines
por: Phillips, Mary E, et al.
Publicado: (2021)

Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial
por: Lipton, Richard B., et al.
Publicado: (2022)

Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QT(c) interval in healthy subjects
por: Darpö, Börje, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_bkv6jd1vn29sm0k5rb71rlnrck